Sophie McGrath is a partner in Goodwin’s Technology and Life Sciences groups. Ms. McGrath focuses on transactions in the life sciences and technology sectors, acting for companies at all stages of development, as well as investors and management teams. She advises on a wide range of corporate matters, including private and public financings, mergers and acquisitions, public offerings and restructurings.

Ms. McGrath is a recommended lawyer for Chambers UK and Legal 500. She is described by Chambers as “a venture capital expert” who serves as a “fantastic adviser” to both investor and company clients. She applies her “very commercial” approach to deals in the life sciences and technology sectors. 

Ms. McGrath also has a keen interest in the impact investment sector, acting for both investors and companies that are targeting a “double bottom line,” either through environmental or social impact, and is a member of the British Venture Capital Association’s Impact Investment advisory group, which has a mandate to promote the development of the impact investment sector in the UK.





  • Advised Achilles Therapeutics, a biopharmaceutical company developing personalised cancer immunotherapies, on the completion of its £52.7 million Series C. 
  • Advised COMPASS Pathways plc on its $146.6 million initial public offering on NASDAQ, and its $80 million crossover round. Compass is a life sciences company dedicated to accelerating patient access to evidence based innovation in mental health.
  • Advised Arix Bioscience Holdings Limited, a global venture capital company focused on investing in and building breakthrough biotech companies, on the completion of its €1.5 million investment into Twelve Bio ApS as part of its €4 million seed round. 
  • Advised Morningside Ventures, and early stage venture investor, on the completion of its £23.7 million investment into Immune Regulation Limited as part of a £40.6 million Series B funding round.
  • Advised a deep tech bio company on the completion of its London-seed round.
  • Advised Rockend Limited, a company aiming to create novel cell therapeutics on its seed financing and subsequent seed extension financing.
  • Advised Novo Holdings A/S, a leading international life sciences investor, on its $40 million investment as part of a $60 million Series C funding round into Exscientia Limited, a world leading AI-driven drug discovery company based in the UK.
  • Advised Achilles Therapeutics, a biopharmaceutical company developing personalised cancer immunotherapies, on the completion of its £100 million Series B crossover round, which was one of the largest growth stage venture rounds for a UK biotech company in 2019.
  • Advised Coöperatieve Gilde Healthcare IV U.A., a specialised European healthcare-focused investment fund based in the Netherlands, on its $10 million investment in Big Health Ltd as part of a $25 million Series B.Big Health’s purpose is to help millions back to good mental health, with digital therapeutics - fully automated and highly personalised behavioural programs for mental health.
  • Advised Advanced Medical Solutions Group plc, an AIM listed life sciences company, on its acquisition of Sealantis Limited, a developer of an alginate-based tissue adhesive technology platform.
  • Advised QuantaDialysis Technologies Limited, a medical device company focused on haemodialysis systems for use in the clinic and home, on its Series C funding round raising over £38 million.
  • Advised Brytlyt Limited, a company that is developing and commercializing GPU-accelerated data processing technology, on its Series A funding round.
  • Advised Wintermute Trading Limited, a leading global algorithmic market maker in cryptocurrency markets, on its $2.8 million Series A.
  • Advised Joanna Dai Limited, a luxury performance workwear brand specializing in sustainable, versatile and high-tech women’s workwear, on its seed funding round.
  • Advised med24 Limited, a new provider of private medical clinics and virtual services for 24/7 immediate access healthcare in London, on its £5 million seed financing.
  • Advised Advent Life Sciences, a leading trans-Atlantic venture investors focused on building innovative Life Sciences businesses in the UK, Europe and the USA, on its £4 million Series A investment into Amphista Therapeutics.
  • Advised Cognitive Credit, a company developing an end-to-end analytics application that delivers cutting edge technology to institutional credit investors, on its convertible loan from the Future Fund and existing investors.
  • Advised Beyond.Life Ltd, providing an online marketplace that connects funeral directors and at-need customers, on its Series A round.
  • Advised Novastar Ventures Limited, an impact investment fund, on its Series A investment in The Sure Chill Company Limited, a company that develops a revolutionary platform cooling technology.
  • Advised N+1 Singer as nominated adviser and broker to Verona Pharma plc, a listed drug development company, in relation to its £44.7 million UK and U.S. placing.*
  • Advised a listed life sciences company in relation to its acquisition of a medical devices business based in the U.S.*
  • Advised Neuroprotexeon Limited, a late clinical-stage pharmaceutical and medical device company, on its initial spinout from Imperial College London, subsequent rounds of private financing and issues relating to the cross border nature of its operations.*
  • Advised Gilde Healthcare Partners B.V. as lead investor on multiple financing rounds into Lumeon Limited, a digital healthcare company.*
  • Advised Novo A/S, Lundbeckfond A/S and Gilde Healthcare Partners B.V. on multiple financing rounds into Acacia Pharma Limited and in relation to its ultimate listing on Euronext. Acacia Limited is a specialty pharmaceutical company focused on the development and commercialisation of new treatments for the conditions arising as a consequence of surgery, cancer or cancer treatment.*
  • Advised Arc Medical Limited, a UK medical devices company, on a partial exit by certain shareholders to Norgine Ventures, along with a strategic investment and working capital facility from Norgine.*
    • Advised Cruncher Technologies Limited, a company using artificial intelligence to solve big data issues for the financial markets, on various financing rounds and its commercialisation into the U.S.*
  • Advised EQ Investors, a B Corporation certified wealth manager (B Corporations are for-profit companies certified as meeting rigorous standards of social and environmental performance, accountability, and transparency), in relation to the acquisition of Truestone Wealth Management, a financial planning firm with £500 million of client assets under management.*
  • Advised Mustard Seed, an impact investment fund, on multiple investments including:*
    • Skin Healthcare, a skin analytics app and device designed to help identify early signs of skin cancer.
    • Beulah, a luxury goods company providing employment opportunities to victims of human trafficking.
    • Switchee, a company seeking to significantly reduce energy use and spending.

* Denotes experience prior to joining Goodwin.

Professional Activities

Ms. McGrath is a member of the British Venture Capital Association.


Ms. McGrath was recognized by Chambers 2021 UK for her work in Private Equity: Venture Capital Investment.

Ms. McGrath has extensive experience in private investment work, acting for companies at all stages of development, as well as investors and management teams. She is a recommended lawyer in Chambers UK 2020 in the field ‘Private Equity: Venture Capital Investment.’

Ms. McGrath has also been ranked by Legal 500 for Venture Capital since 2013 and in 2017 for M&A: Smaller Deals, up to £50 million and is described as “very resourceful and knowledgeable.”


In The News









Qualified Lawyers Transfer Test, 2003
College of Law London
Graduate Diploma in Law, 1999
College of Law, Sydney
Bachelors in Commerce and Laws, 1998
University of Sydney



Solicitor of the Senior Courts of England and Wales
New South Wales, Australia
Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique